Céline Dubath, PhD, is affiliated with the Unit of Pharmacogenetics and Clinical Psychopharmacology at the Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Switzerland. Her published work from 2019 to 2022 in Psychiatrist.com focuses on metabolic disorders and schizophrenia/schizoaffective disorders, including studies on the effects of risperidone on weight and metabolic parameters, cardiometabolic risk assessment in psychiatric populations, and lipid disturbances in adolescents treated with second-generation antipsychotics. She has frequently collaborated with co-authors such as Chin B. Eap, Philippe Conus, Alessandra Solida, Anaïs Glatard, and Armin von Gunten.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
